Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14644853 | 0.73 | — | — | |
| SCHEMBL4412627 | 0.72 | — | — | |
| SCHEMBL136590 | 0.70 | — | — | |
| SCHEMBL11104666 | 0.67 | — | — | |
| SCHEMBL19321762 | 0.67 | TSHR (0.36) | TSHRTDP1 | |
| SCHEMBL1470239 | 0.67 | — | — | |
| SCHEMBL3808233 | 0.65 | — | — | |
| SCHEMBL106433 | 0.65 | — | — | |
| SCHEMBL2148543 | 0.64 | TSHR (0.33) | TSHRTDP1 | |
| SCHEMBL1470135 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113166090-A | Chroman-6-ols having extended lipophilic side chains in position 2, their manufacture and use | 帝斯曼知识产权资产管理有限公司 | 2021-07-23 | — | — | CN | claimed |
| US-20210130314-A1 | NOVEL USE OF SUBSTITUTED CHROMAN-6-OLS WITH EXTENDED LIPOPHILIC SIDE CHAINS | DSM IP ASSETS B.V. (NL) | 2021-05-06 | — | — | US | claimed |
| EP-3774758-A2 | NOVEL USE OF SUBSTITUTED CHROMAN-6-OLS WITH EXTENDED LIPOPHILIC SIDE CHAINS | DSM IP Assets B.V. (NL) | 2021-02-17 | — | — | EP | claimed |
| EP-3774757-A1 | CHROMAN-6-OLS WITH AN EXTENDED LIPOPHILIC SIDE CHAIN IN POSITION 2, THEIR MANUFACTURE AND USE | DSM IP Assets B.V. (NL) | 2021-02-17 | — | — | EP | claimed |
| WO-2021005508-A1 | METHODS FOR PRODUCING TRIS(HALOSULPHONYL)METHANE OR SALTS OF SAME | SCE FRANCE (FR) | 2021-01-14 | — | — | WO | claimed |
| WO-2020043995-A1 | POLYMER, METHOD FOR THE PRODUCTION THEREOF, COMPOSITION COMPRISING SAME, AND USE IN BATTERIES | ARKEMA FRANCE (FR) | 2020-03-05 | — | — | WO | claimed |
| WO-2019185938-A2 | NOVEL USE OF SUBSTITUTED CHROMAN-6-OLS WITH EXTENDED LIPOPHILIC SIDE CHAINS | DSM IP ASSETS B.V. (NL) | 2019-10-03 | — | — | WO | claimed |
| WO-2019185904-A1 | CHROMAN-6-OLS WITH AN EXTENDED LIPOPHILIC SIDE CHAIN IN POSITION 2, THEIR MANUFACTURE AND USE | DSM IP ASSETS B.V. (NL) | 2019-10-03 | — | — | WO | claimed |
| EP-1520318-B1 | REINFORCED IONIC CONDUCTING MATERIAL, USE THEREOF IN ELECTRODES AND ELECTROLYTES | INST POLYTECHNIQUE GRENOBLE (FR) | 2016-08-10 | — | — | EP | claimed |
| JP-4361137-B2 | — | — | 2009-11-11 | — | — | JP | claimed |
| EP-1520318-A2 | REINFORCED IONIC CONDUCTING MATERIAL, USE THEREOF IN ELECTRODES AND ELECTROLYTES | INSTITUT NATIONAL POLYTECHNIQUE DE GRENOBLE (FR) | 2005-04-06 | — | — | EP | claimed |
| WO-2004001888-A2 | REINFORCED IONIC CONDUCTING MATERIAL, USE THEREOF IN ELECTRODES AND ELECTROLYTES | INSTITUT NATIONAL POLYTECHNIQUE DE GRENOBLE (FR) | 2003-12-31 | — | — | WO | claimed |
| EP-0890176-B1 | PROTON CONDUCTOR IN LIQUID FORM | HYDRO QUEBEC (CA) | 2001-06-20 | — | — | EP | claimed |
| US-6120696-A | MIXTURE OF IMIDAZOLES OR TRIAZOLES OR THEIR POLYMERS WITH THEIR SALTS OF PERFLUOROALKYLSULFONIC OR SULFINIC ACIDS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2000-09-19 | — | — | US | claimed |
| JP-2000508114-A | — | — | 2000-06-27 | — | — | JP | claimed |
| EP-0890176-A1 | PROTON CONDUCTOR IN LIQUID FORM | HYDRO-QUEBEC (CA) | 1999-01-13 | — | — | EP | claimed |
| WO-1998029877-A1 | PROTON CONDUCTOR IN LIQUID FORM | HYDRO-QUEBEC (CA) | 1998-07-09 | — | — | WO | claimed |
| JP-6338349-A | — | — | None | — | — | JP | disclosed |
| EP-0626734-A2 | Rechargeable galvanic lithiumcell | VARTA Batterie Aktiengesellschaft (DE) | 1994-11-30 | — | — | EP | disclosed |
| US-4818644-A | ORGANOMETALLIC SALT IN SOLVENT; ELECTROLYTE FOR ELECTROCHEMICAL GENERATORS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 1989-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130314-A1 | NOVEL USE OF SUBSTITUTED CHROMAN-6-OLS WITH EXTENDED LIPOPHILIC SIDE CHAINS | C1S, FFAR3, FFAR1 | TSHR 667/4885TDP1 3191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.